StockTipsArenaBeta

BUY Biocon Ltd — Axis Securities

BUYBiocon Ltd
Biocon share price target & all analyst calls

byAxis SecuritiesHorizon: NA (inferred 1–3 months)19 Sept 2026via Economic Times New Stock Recos

Entry₹385Inferred
Target₹424
Total upside +10.13%
Stop lossNot given
CMP₹365.11d ago
Active-5.17%+16.13%upside left 6 wk left
Follow Axis Securities for new callsGet alertsWatch BIOCON for new buy/sell callsGet alertsSee 1 other Short-term call on BIOCONSee 74 other Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Nov, 5:21 pm IST
18 supporting8 neutral4 opposing
Supports the BUY call (18)

MACD above its signal line — bullish momentum

Technicals · macd·7 Nov · today

Biocon shares upgraded by Kotak Institutional Equities after recent correction improves risk-reward

NewsCnbc-Tv18·5 Nov · 2d ago

(opens in new tab)

7 advisors have active long-term BUY calls on this stock, with 2 issued in the last 14 days

Advisor consensus · adjacent horizon·5 Nov · 2d ago

Biocon gets additional global market entry for Yesintek to treat autoimmune diseases

NewsCnbc-Tv18·26 Oct · 2w ago

(opens in new tab)

Biocon settles licence agreement with Genetech for cancer treatment drug — Check earliest secured launch dates

NewsCnbc-Tv18·14 Oct · 3w ago

(opens in new tab)
Neutral / worth noting (8)

Biocon reported Q2 FY27 consolidated financial results with total income of Rs 4,423 crore, EBITDA of Rs 865 crore, and net profit of Rs 41 crore.

NSE · Press Release·4 Nov · 3d ago

(opens in new tab)

Biocon reported Q2 FY27 consolidated financial results with total income of Rs 4,423 crore, EBITDA of Rs 865 crore, and net profit of Rs 41 crore.

BSE · Company Update·4 Nov · 3d ago

(opens in new tab)

Biocon Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·4 Nov · 3d ago

(opens in new tab)

Q2 Results Today Highlights: BSE, Apollo Hospitals, Sundaram Finance post higher profit in Q2; Biocon, Zydus Life profit declines

NewsHbl·4 Nov · 3d ago

(opens in new tab)
Weighs against the BUY call (4)

Biocon Q2 Results: Net Profit Falls 51% To Rs 41 Crore, Revenue Rises 2% YoY; Misses Estimates

NewsNdtv-Profit·4 Nov · 3d ago

(opens in new tab)

1 other SEBI-registered advisor has an active short-term SELL call on this stock

Advisor consensus · same horizon·9 Oct · 4w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Biocon

All analyst calls on Biocon

More from Axis Securities

Every call and its outcome